We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2019 to May 2024
By Nathan Allen
Roche Holding AG (RO.EB) said Friday that long-term data confirm its Gazyva cancer drug extends the lives of people with a chronic form of leukemia compared with its MabThera treatment.
After a follow-up period of five years, data from the final analysis of Roche's CLL11 study show a 51% reduction in the risk of disease progression or death in patients treated with Gazyva, compared with patients treated with its MabThera medication, the company said.
Gazyva is approved for use in combination with chlorambucil in more than 90 countries, Roche said.
Write to Nathan Allen at nathan.allen@dowjones.com
(END) Dow Jones Newswires
June 15, 2018 03:05 ET (07:05 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
